Patents by Inventor Roopa Rai

Roopa Rai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10189826
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 29, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat
  • Publication number: 20180208577
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Patent number: 10030004
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: July 24, 2018
    Assignee: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Publication number: 20180051013
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat
  • Patent number: 9670172
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 6, 2017
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma
  • Publication number: 20170137410
    Abstract: Fused cycloalkyl-pyrimidine compounds that are kinase inhibitors, such as multi-kinase inhibitors, are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused cycloalkyl-pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused cycloalkyl-pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: May 18, 2017
    Applicant: Medivation Technologies, Inc
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI, Anil Kumar AGARWAL
  • Publication number: 20170119907
    Abstract: This disclosure describes compositions and methods for delivering and localizing therapeutic agents to therapeutic targets. This disclosure also provides multivalent forms of cationic dyes (“cationic dye multimers”) and methods by which these compounds can be used to treat joint injuries.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 4, 2017
    Applicant: Medivation Technologies, Inc.
    Inventors: David Hung, Sarvajit Chakravarty, Roopa Rai, Sebastian Bernales, Balaji Dashrath Sathe, Gonzalo Ureta, Emma McCullagh
  • Patent number: 9499519
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: November 22, 2016
    Assignee: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green, Amantullah Ansari
  • Publication number: 20160326137
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: December 31, 2014
    Publication date: November 10, 2016
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Naveen Chaklan, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Publication number: 20160272645
    Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 22, 2016
    Applicant: Medivation Technologies, Inc.
    Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahmam PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
  • Patent number: 9422267
    Abstract: The present invention provides fused pyrimidine compounds of the general Formula (I): or a salt thereof, wherein the variables are as defined in the specification. Fused pyrimidine compounds of the general Formula (I) are provided as kinase inhibitors, such as multi-kinase inhibitors. In one aspect, fused pyrimidine compounds of the general Formula (I) are provided as IGF-IR inhibitors. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compounds of the general Formula (I) and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound of the general Formula (I) or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: August 23, 2016
    Assignee: Medivation Technologies, Inc.
    Inventors: Sarvajit Chakravarty, Roopa Rai, Michael John Green
  • Publication number: 20160068513
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. Fused pyrimidine compounds that are inhibitors of Trk receptors (e.g., Trk A, Trk B and Trk C) are provided also. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: December 26, 2013
    Publication date: March 10, 2016
    Applicant: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN, Amantullah ANSARI
  • Patent number: 9181280
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: November 10, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Patent number: 9162986
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 20, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young
  • Publication number: 20150065519
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma
  • Publication number: 20140378453
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 25, 2014
    Inventors: Aleksandr KOLESNIKOV, Roopa RAI, William Dvorak SHRADER, Steven M. TORKELSON, Kieron E. WESSON, Wendy B. YOUNG
  • Publication number: 20140221667
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Daniel A. DICKMAN, Dange Vijay KUMAR, Colin O'BRYAN, Roopa RAI, William Dvorak SHRADER
  • Patent number: 8778625
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: July 15, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Aleksandr Kolesnikov, Roopa Rai, William Dvorak Shrader, Steven M. Torkelson, Kieron E. Wesson, Wendy B. Young
  • Publication number: 20140179668
    Abstract: Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.
    Type: Application
    Filed: December 26, 2013
    Publication date: June 26, 2014
    Applicant: MEDIVATION TECHNOLOGIES, INC.
    Inventors: Sarvajit CHAKRAVARTY, Roopa RAI, Michael John GREEN
  • Patent number: 8729117
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: May 20, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader